Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Randomized, Double Blind, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Subcutaneous Bay 50-4798 Administration in Patients With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to Patients on HAART Alone.

NCT00059462 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00059462
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00059462 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Randomized, Double Blind, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Subcutaneous Bay 50-4798 Administration in Patients With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to Patients on HAART Alone.
Lead sponsor
Bayer
Phase
Phase 1/2
Overall status
Completed
Start date
December 31, 2002
Completion date
March 31, 2005
Enrollment
56 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections